A multicenter phase IIb trial in adults with mild-to-moderate atopic dermatitis shows that a 3% topical JAK1/2 inhibitor gel applied twice daily cuts EASI scores by over 80% at 8 weeks, outperforming once-daily use and far exceeding placebo. Both active regimens improved global assessment, EASI‑50/75/90 responses, and quality-of-life measures, with adverse event rates nearly identical to vehicle and plasma drug levels in the picogram range, indicating very low systemic exposure. These data position high-strength topical JAK inhibition as a potent, well-tolerated option to bridge the gap between emollients/topical steroids and systemic agents in chronic AD management .
Dive into the trial details to see where a strong yet skin-limited JAK gel might fit in your AD ladder. To Learn more Click Here ##Reference## Zhang L, Wang M, Zhang L, et al. Efficacy and safety of pumecitinib 3% gel in…
